This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Transactions

Oct. 31, 2000

Orrick Herrington: MERGING DRUG COMPANIES CREATE POWERFUL TEAM

Corixa Corp. has agreed to acquire all outstanding shares of Coulter Pharmaceutical Inc. The deal is valued in excess of $900 million. Seattle-based Corixa is a biotechnology company focusing on the research and development of immunotherapuetic products that treat autoimmune diseases, cancers and infectious diseases.

        Corixa Corp. has agreed to acquire all outstanding shares of Coulter Pharmaceutical Inc. The deal is valued in excess of $900 million.
        Seattle-based Corixa is a biotechnology company focusing on the research and development of immunotherapuetic products that treat autoimmune diseases, cancers and infectious diseases. The company is currently developing vaccines for skin, breast,...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up